IL6 and in situ carcinoma: Du et al. (2022) identified heightened SASP-related factors, particularly IL-6 and IL-1β, in CIS-treated mouse ovaries (Du et al., 2022). Similarly, another study demonstrated increased expression of several common SASPs, such as IL-6, MCP-1, and TGF-β1, in mouse ovaries following DOX treatment (Gao et al., 2023).